Physician profile
Cristina S Ricketti
NPI 1376914713
$1,807.83
in general payments reported to CMS, 2019-2025
10 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family Health provider received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $278 · 2023: $101 · 2024: $760 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,176.76 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $476.14 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Blueprint Medicines Corporation | $33.57 | 2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $19.42 | 2025 | Eohilia |
| Genentech USA, INC. | $18.73 | 2024 | Xolair |
| Electromed, INC. | $18.71 | 2024 | Smartvest |
| Csl Behring | $17.03 | 2025 | Haegarda |
| Kaleo, INC. | $16.39 | 2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.06 | 2024 | Spiriva Respimat |
| Hikma Pharmaceuticals USA | $15.02 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Ricketti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.